Data for this systematic review are drawn from the papers included. These are referenced in the manuscript and are accessible in the public repositories described in the attached protocol.

Introduction {#sec005}
============

Chronic respiratory diseases (CRDs) are the fourth leading cause of non-communicable disease (NCD) deaths globally, and pose a particular challenge to low and middle-income countries (LMICs) where risk factors for respiratory damage including poverty-related in-utero and early childhood exposures\[[@pone.0161176.ref001]\], exposure to acute respiratory infections\[[@pone.0161176.ref002]\], indoor biomass fuel exposure\[[@pone.0161176.ref003], [@pone.0161176.ref004]\], a rising prevalence of smoking\[[@pone.0161176.ref005]\], chronic HIV-infection\[[@pone.0161176.ref006]\], and pulmonary tuberculosis (PTB) intersect. A high prevalence of CRDs has been demonstrated in LMICs, and these are expected to have a substantial impact on population health and health-services in the coming years\[[@pone.0161176.ref007]--[@pone.0161176.ref010]\]. An improved understanding of the nature of CRDs in LMICs, their natural history, and associated morbidity and mortality is required if we are to design appropriate prevention, diagnostic, and management strategies\[[@pone.0161176.ref011], [@pone.0161176.ref012]\].

Pulmonary TB remains an important cause of chronic respiratory impairment in LMICs. 5.2 million incident cases of PTB were reported globally in 2014\[[@pone.0161176.ref013]\], and the presence of long term respiratory sequelae following PTB treatment is well established \[[@pone.0161176.ref014], [@pone.0161176.ref015]\]. Pulmonary granuloma formation, tissue necrosis and liquefaction, and aberrant healing responses are known features of TB disease\[[@pone.0161176.ref016], [@pone.0161176.ref017]\]. The persistence of abnormal airway physiology after treatment has been documented in large population-based cross-sectional studies which show 1.37--2.94 higher odds of fixed airways obstruction in those with a history of PTB, compared to those without\[[@pone.0161176.ref015], [@pone.0161176.ref018]--[@pone.0161176.ref021]\]. Previous TB has also been associated with chronic respiratory symptoms in LMICS: previous TB was the strongest predictor of chronic bronchitis within the 1996 South African Demographic & Health Survey \[[@pone.0161176.ref022]\] and the odds of a medical diagnosis of bronchiectasis were over 3-fold higher in those who had a history of TB, compared to those who had not, in a population based study of 10,811 adults in China \[[@pone.0161176.ref023]\].

Whilst the evidence for abnormal spirometry and symptoms following PTB disease in LMICS is clear, imaging of patients completing PTB treatment is not routinely performed, and our understanding of the associated patterns of structural lung pathology remains limited. Without these imaging data, we are not yet able to accurately phenotype patterns of post-TB lung disease in to the meaningful categories required for clinical management, prognostication, and ongoing research into the risk factors for post-TB lung damage \[[@pone.0161176.ref024], [@pone.0161176.ref025]\]. In addition, information on the morbidity and mortality associated with post-TB lung damage remains limited, but would be timely given the post-2015 TB agenda, which recognises the need for TB services to mitigate the long-term detrimental impact of TB disease on patients' lives and livelihoods \[[@pone.0161176.ref026]\].

In this review we seek to improve our understanding of the nature and impact of post-TB lung disease. We examine the literature on imaging defined structural post-TB lung damage, and its relationship to patient-centred outcomes including functional impairment, respiratory symptoms, and health-related quality of life. We have included studies using both plain chest radiographs (CXR) and more detailed computerised tomography (CT) imaging in our review: CXR is widely available for use in TB screening and diagnosis and may be of programmatic use in the diagnosis and management of post-TB lung damage, but CT provides a higher level of detail and may provide more information on the true nature of this damage.

Methods {#sec006}
=======

A protocol driven literature search was performed following PRISMA guidelines to identify studies in which consecutive participants with pleural, miliary, or pulmonary TB were recruited, where CXR or CT was performed after the completion of a full medical TB treatment regimen, and where the prevalence of abnormal imaging or the severity of residual structural lung damage was reported ([S1 File](#pone.0161176.s001){ref-type="supplementary-material"}). Cohort studies, cross-sectional studies and randomised control trials (RCTs) were eligible for inclusion. There were no limits on publication date. Only studies published in English were included.

Literature searches were conducted in Medline, Pubmed, Scopus, Web of Science, and the Cochrane Library (July 2016) ([Table 1](#pone.0161176.t001){ref-type="table"}). Reference lists from published reviews and reference and citation lists of papers meeting inclusion criteria were reviewed to identify additional articles.

10.1371/journal.pone.0161176.t001

###### Template for literature search: Pulmonary, pleural or military tuberculosis AND \[CXR imaging OR CT imaging\].

![](pone.0161176.t001){#pone.0161176.t001g}

  Criteria                                      Search terms
  --------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------
  Pulmonary, pleural, or miliary tuberculosis   "Tuberculosis, pulmonary"\[Mesh\] OR "tuberculosis, miliary\[Mesh\] OR "tuberculosis, pleural"\[Mesh\] OR \"pulmonary TB\" OR \"pulmonary tuberculosis\"
  CXR Imaging                                   "thoracic radiography\"\[MeSH\] OR "chest x-ray\" OR \"chest radiograph\" OR \"CXR\"
  CT imaging                                    "computed tomography"\[MeSH\] OR \"CT\" OR \"comput\* tomography\"

The title and abstract of all identified studies were screened by two independent reviewers (JM and HS). Full text review was performed on all selected articles. Studies restricted to paediatric populations, in whom PTB has a varied presentation, or patients with non-HIV related immunosuppression (chemotherapy, malignancy etc.) where imaging was likely to be affected by comorbidities, were excluded. Data from the control arms of trials of adjuvant immunomodulatory therapies, in which patients received medical TB treatment only, were included.

A standardized data extraction form was used by 2 authors (JM and HS) to determine the primary outcome of interest, which was the prevalence of abnormal imaging after TB treatment. Information was collected on the patterns of imaging pathology, study characteristics, participant characteristics, treatment regimens, and the modality and timing of thoracic imaging. We recorded the proportion of studies that presented a measure of association between imaging findings and other clinical parameters including spirometry, functional capacity, respiratory symptoms, or health-related quality of life. Disagreements in study selection and data extraction were resolved by discussion. Subgroup analyses were conducted to explore the effect of different manifestations of disease (pleural vs. pulmonary), imaging modality (CXR vs. CT), and multidrug-resistant (MDR) disease on the primary outcome. A narrative analysis was conducted.

Study quality was determined using a modified version of the Newcastle-Ottowa score\[[@pone.0161176.ref027]\], which included assessment of selection bias, adequacy of follow-up, the accuracy with which baseline TB disease and treatment completion were determined, the quality and standardisation of imaging interpretation, and the exclusion of those with structural lung disease preceding TB-disease. A maximum score of 5 was possible for cohort studies, and 4 for cross-sectional studies where no follow-up was required.

Results {#sec007}
=======

We identified 10,740 articles, with 6909 articles remaining after removal of duplicates. Title and abstract review identified 309 articles for full text review, of which 277 were excluded for reasons including non-consecutive patient recruitment, imaging prior to treatment completion, and failure to report the absolute prevalence or severity of residual lung damage. Reference and citation searches identified 5 further articles for inclusion, giving a total of 37 articles ([Fig 1](#pone.0161176.g001){ref-type="fig"}).

![PRISMA flow chart.](pone.0161176.g001){#pone.0161176.g001}

These papers covered the time period 1973--2015. They included 16 prospective cohort studies with patients recruited at TB diagnosis and imaged upon treatment completion, and one prospective cohort study where imaging was performed 1 year post treatment completion\[[@pone.0161176.ref028]\]. There were 7 cross-sectional studies, 5 of which performed imaging at various time points after treatment completion, and 7 retrospective cohort studies, which performed imaging upon treatment completion. Data from 6 RCTs were included: data from both study arms were included for two treatment regimen trials \[[@pone.0161176.ref029], [@pone.0161176.ref030]\] and a study investigating the effect of Vitamin-D and L-arginine supplementation\[[@pone.0161176.ref031]\], but data from the control arms only were included from trials investigating prednisolone use\[[@pone.0161176.ref032], [@pone.0161176.ref033]\], and a trial of *M*. *vaccae* immunomodulation\[[@pone.0161176.ref034]\]. All RCTs performed imaging at treatment completion, and 1 also performed serial imaging 6-months later\[[@pone.0161176.ref032]\]. Only seven studies used CT imaging to describe structural pathology. Five of these were conducted in the Americas, and all performed imaging at treatment completion. Only one study of pleural disease used both CXR and CT imaging\[[@pone.0161176.ref032]\].

The total number of patients in all included studies was 4870, with disaggregated data available for 76 HIV-infected individuals. The median number of participants per study was 131 (range 13--1080). Studies were conducted in the Americas (n = 11), South East Asia (n = 9), Europe (n = 6), the Western Pacific region (n = 6), and Africa (n = 2). Both of the studies conducted in Africa were from South Africa and focused on either pleural\[[@pone.0161176.ref032]\] or MDR disease\[[@pone.0161176.ref035]\]. 26 studies focused on PTB, 1 on the sequelae of miliary TB, 9 were restricted to pleural TB, and 1 included patients with pulmonary, pleural or mediastinal TB\[[@pone.0161176.ref036]\]. The marked heterogeneity between studies made meta-analysis of their findings inappropriate.

Few studies specified the pattern of drug sensitivity (12/37), or previous episodes of TB (10/37). Two studies of residual lung damage in patients receiving TB retreatment were included, one of which was restricted to MDR patients\[[@pone.0161176.ref034], [@pone.0161176.ref037]\]. Two additional studies of patients with MDR disease but unspecified histories of TB treatment were identified\[[@pone.0161176.ref035], [@pone.0161176.ref038]\]. The treatment regimens used varied widely; only 7 studies specified use of the gold standard short-course treatment regimen, and only 2 out of 3 studies of MDR disease specified the use of national treatment guidelines\[[@pone.0161176.ref035], [@pone.0161176.ref037]\].

Pulmonary disease {#sec008}
-----------------

Of the 27 studies reporting the sequelae of pulmonary and miliary TB, prevalence estimates for radiographic pathology were given in 17 CXR ([Table 2](#pone.0161176.t002){ref-type="table"}) and 5 CT studies ([Table 3](#pone.0161176.t003){ref-type="table"}), and varied widely. Twelve CXR studies reported the prevalence of cavitation (8.3--83.7%), 3 reported fibrosis (prevalence 25.0--70.4%) and 4 reported bronchiectasis (prevalence 4.3--11.2%). The CT-based studies generally reported a lower prevalence of cavitation (7.4--34.6%), and a higher prevalence of bronchiectasis (35.0--86.0%) and fibrosis (70.0--92.6%), than studies using CXR imaging. A more diverse range of pathologies was noted on CT imaging: pleural thickening was reported in 3 studies (prevalence 0.1--50.0%, n = 99), features potentially suggestive of ongoing inflammation such as nodules were seen in all 5 studies (prevalence 25.9--55.8%, n = 193), consolidation was reported in 4 studies (3.7--19.2%, n = 119), emphysema was seen in in 2 studies (prevalence 15.4--45.0%, n = 72), and mosaicism was documented in 1 study (prevalence 70%, n = 20). A broad range of severity scores were used to quantify residual damage in 13 studies of PTB sequelae, only one of which was validated for scoring post-TB damage rather than active PTB disease\[[@pone.0161176.ref039]\] ([Table 4](#pone.0161176.t004){ref-type="table"}).

10.1371/journal.pone.0161176.t002

###### Studies reporting prevalence of imaging patterns on CXR imaging following treatment for thoracic tuberculosis.
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  Timing of imaging               Author, Year                                                                       Country        Study design                                                             TB pattern                        Participant HIV status       Treatment episode   Drug sensitivity   Number of participants          Prevalence of pathology (%)                                                                                                               Quality score
  ------------------------------- ---------------------------------------------------------------------------------- -------------- ------------------------------------------------------------------------ --------------------------------- ---------------------------- ------------------- ------------------ ------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------- ---------------
  On completion of TB Treatment   Yu, 1995\[[@pone.0161176.ref040]\]                                                 Taiwan         Prospective cohort                                                       Pulmonary                         Negative                     Not specified       Mixed              22                              Abnormal imaging: 13.6%                                                                                                                   3/5
                                  Al Hajjaj, 2000 \[[@pone.0161176.ref041]\]                                         Saudi Arabia   Prospective cohort                                                       Pulmonary                         Not specified                Not specified       Not specified      1080                            Abnormal imaging: 65.9%, Cavitation: 15.0%, Pleural thickening 6.9%, Lung destruction 52.4%                                               3/5
                                  de Valliere, 2004\[[@pone.0161176.ref035]\]                                        South Africa   Prospective cohort                                                       Pulmonary                         Mixed                        Not specified       MDR                33                              Abnormal imaging: 93.9--100%, Cavitation: 51.5%--69.7%                                                                                    2/5
                                  Buyokoglan, 2007 \[[@pone.0161176.ref042]\]                                        Turkey         Prospective cohort                                                       Pulmonary                         Negative                     Not specified       Not specified      25                              Cavitation: 28.0%                                                                                                                         3/5
                                  Swaminathan, 2007 \[[@pone.0161176.ref043]\]                                       India          Prospective cohort                                                       Miliary                           Positive                     Not specified       Not specified      31                              Abnormal imaging: 22.6%. Lung destruction: 3.2%                                                                                           3/5
                                  Angthong, 2011 \[[@pone.0161176.ref044]\]                                          Thailand       Prospective cohort                                                       Pulmonary                         Mixed---data disaggregated   First episode       Not specified      98 HIV+                         Abnormal imaging: 84.7%, Cavitation: 11.2%, Fibrosis: 70.4%, Bronchiectasis: 11.2%                                                        4/5
  12 HIV-                         Abnormal imaging: 41.7%, Cavitation: 8.3%, Fibrosis: 25.0%, Bronchiectasis: 8.3%                                                                                                                                                                                                                                                                                                                                                                           
                                  Small, 1994 \[[@pone.0161176.ref045]\]                                             America        Retrospective cohort                                                     Pulmonary                         Positive                     Not specified       Not specified      13                              Abnormal imaging: 23.1%                                                                                                                   3/5
                                  Menon, 2015 \[[@pone.0161176.ref036]\]                                             India          Retrospective cohort                                                     Pulmonary, pleural, mediastinal   Not specified                First episode       Not specified      441                             Abnormal imaging: 40.4, Cavitation: 21.4%, Pleural thickening: 21.2%, Fibrosis: 38.7%, Bronchiectasis: 4.3%, Mediastinal lesions: 23.6%   2/5
                                  Kallan, 1988 \[[@pone.0161176.ref046]\]                                            India          Cross sectional                                                          Pulmonary                         Not specified                Not specified       Not specified      119                             Abnormal imaging: 100.0%, Cavitation: 42.0%, Bronchiectasis: 7.6%                                                                         1/4
                                  Anonymous, 1973 \[[@pone.0161176.ref029]\]                                         India          RCT--TB treatment regimens[\*](#t002fn001){ref-type="table-fn"}          Pulmonary                         Not specified                Not specified       Not specified      173                             Cavitation: 49.7%                                                                                                                         4/5
                                  Hamilton, 2008 \[[@pone.0161176.ref030]\]                                          America        RC --TB treatment regimens[\*](#t002fn001){ref-type="table-fn"}          Pulmonary                         Negative                     Not specified       Fully sensitive    834                             Cavitation: 23.3%                                                                                                                         4/5
                                  Kenangalem, 2013 \[[@pone.0161176.ref031]\]                                        Indonesia      RCT--additional Vit D / L-arginine[†](#t002fn002){ref-type="table-fn"}   Pulmonary                         Mixed                        First episode       Mixed              77                              Cavitation: 18.2%                                                                                                                         2/5
  On completion and at 6m         Corlan, 1997 \[[@pone.0161176.ref034]\]                                            Romania        RCT--additional M.vaccae[†](#t002fn002){ref-type="table-fn"}             Pulmonary                         Retreatment                  Mixed               Mixed              43 with imaging on completion   Cavitation: 83.7%                                                                                                                         3/5
  32 with imaging at 6 months     Cavitation: 68.8%                                                                                                                                                                                                                                                                                                                                                                                                                                          
  6--63 months post completion    Singla, 2009 \[[@pone.0161176.ref038]\]                                            India          Cross sectional                                                          Pulmonary                         Negative                     Not specified       MDR                45                              Abnormal imaging: 97.8%, Cavitation: 53.3%                                                                                                1/4
  14--18 years post completion    Banu Rekha, 2009 \[[@pone.0161176.ref047]\]                                        India          Cross sectional                                                          Pulmonary                         Not specified                First episode       Not specified      198                             Abnormal imaging: 85.9%                                                                                                                   1/4
  5 years post completion         Lisha, 2012 \[[@pone.0161176.ref048]\]                                             India          Cross sectional                                                          Pulmonary                         Not specified                Mixed               Mixed              224                             Abnormal imaging: 65.6%                                                                                                                   2/4
  0--252 months post completion   Baez-saldana, 2013 \[[@pone.0161176.ref039]\]                                      Mexico         Cross sectional                                                          Pulmonary                         Mixed                        Not specified       Not specified      127                             Abnormal imaging: 96.9%                                                                                                                   2/4

\*Data included from both arms

^†^Data included from placebo arms only

10.1371/journal.pone.0161176.t003

###### Studies reporting prevalence of imaging patterns on CT imaging on completion of treatment for pulmonary tuberculosis.

![](pone.0161176.t003){#pone.0161176.t003g}

  Author, Year                                Country      Study design         Participant HIV status   Treatment episode   Drug sensitivity   Number of participants   Prevalence of pathology (%)                                                                                                                                                                                                             Quality score
  ------------------------------------------- ------------ -------------------- ------------------------ ------------------- ------------------ ------------------------ --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------
  Poey, 1997\[[@pone.0161176.ref049]\]        Martinique   Prospective cohort   Negative                 Not specified       Not specified      27                       Cavitation: 7.4%, Bronchiectasis: 85.2%, Fibrosis: 92.6%, Pleural thickening: 4.8%, Nodules: 25.9%, Consolidation: 3.7%, Ground glass pattern: 7.4%, Reticulation: 44.4%,                                                               3/5
  Long, 1998 \[[@pone.0161176.ref050]\]       Canada       Prospective cohort   Negative                 Not specified       Fully sensitive    20                       Bronchiectasis: 50.0%, Fibrosis: 80.0%, Pleural thickening: 0.1%, Nodules: 55.0%, Consolidation: 15.0%, Emphysema/Bullae: 45.0%, Mosaicism: 70.0%                                                                                       3/5
  Bombarda, 2003 \[[@pone.0161176.ref051]\]   Brazil       Prospective cohort   Negative                 Not specified       Not specified      20                       Cavitation: 30.0%, Bronchiectasis: 35.0%, Fibrotic bands: 70.0%, Nodules: 55.0%, Consolidation: 15.0%, Mass lesions: 45%                                                                                                                3/5
  Lee, 2008 \[[@pone.0161176.ref052]\]        Taiwan       Prospective cohort   Negative                 First episode       Fully sensitive    52                       Cavitation: 34.6%, Bronchiectasis: 44.2%, Fibrosis: 92.3%, Pleural thickening: 50.0%, Nodules: 55.8%, Consolidation: 19.2%, Emphysema/Bullae: 15.4%, Mass lesions: 7.7%, Ground glass pattern: 1.9%, Parenchymal calcification: 11.5%   1/5
  Rufino, 2015\[[@pone.0161176.ref053]\]      Brazil       Prospective cohort   Not specified            Not specified       Not specified      74                       Cavitation: 16%, Bronchiectasis: 86%, Nodules: 48%, Parenchymal opacities: 25%, Parenchymal calcifications: 47%, Architectural distortion: 91%                                                                                          1/5

10.1371/journal.pone.0161176.t004

###### Studies reporting severity scores of residual changes on CXR imaging performed following treatment for pulmonary TB.
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  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author                                                                      Country        Study design               n                                           Participant HIV status   Treatment episode   Drug sensitivity   Timing of imaging                                                         Source of severity score                                                                     Severity score description                                                         Findings                                                                                                                          Quality score
  --------------------------------------------------------------------------- -------------- -------------------------- ------------------------------------------- ------------------------ ------------------- ------------------ ------------------------------------------------------------------------- -------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------- ---------------
  de Valliere, 2004 \[[@pone.0161176.ref035]\]                                South Africa   Prospective cohort         33                                          Mixed                    Not specified       MDR                On completion                                                             Not specified                                                                                CXR split into 6 zones. Involvement of each zone scored 0--3. Total score 18.      Mean score 6.5/18                                                                                                                 2/5

  Ralph, 2010 \[[@pone.0161176.ref054]\]                                      Indonesia      Prospective cohort         152                                         Mixed                    Not specified       Mixed              On completion                                                             Ralph 2010---diagnostic CXR scoring system                                                   \% lung affected + 40 if cavitation seen. Total score 140.                         Median score 10/140, Range 0--115                                                                                                 3/5

  Wang, 2010 \[[@pone.0161176.ref028]\]                                       Taiwan         Prospective cohort         98                                          Negative                 Not specified       Not specified      1 year post completion                                                    Not specified                                                                                Minimal / Moderate / Advanced fibrosis[\*](#t004fn001){ref-type="table-fn"}        60.2% Minimal; 14.3% Moderate; 25.5% Advanced                                                                                     3/5

  Chen, 2011 \[[@pone.0161176.ref055]\]                                       Taiwan         Prospective cohort         51                                          Negative                 Not specified       Not specified      On completion                                                             McAdams & Erasmus 1995---active TB CXR scoring system                                        Minimal / Extensive[†](#t004fn002){ref-type="table-fn"}                            31.4% Extensive                                                                                                                   3/5

  Menon, 2015\[[@pone.0161176.ref036]\][‡](#t004fn003){ref-type="table-fn"}   India          Retrospective cohort       441                                         Not specified            First episode       Fully sensitive    On completion                                                             1969 National TB associate of the USA---diagnostic CXR scoring system                        Minimal / Moderate / Moderately advanced / Far advanced                            55.7% Minimal; 22.8% Moderate; 15.2% Moderately advanced; 6% Advanced                                                             2/5

  How, 2014 \[[@pone.0161176.ref056]\]                                        Malaysia       Retrospective cohort       156                                         Mixed                    Mixed               Not specified      On completion                                                             1961 National TB association USA -diagnostic CXR scoring system \[[@pone.0161176.ref057]\]   Minimal / Moderate / Advanced disease[^¶^](#t004fn004){ref-type="table-fn"}        26.2% Minimal; 60.8% Moderate; 13% Advanced                                                                                       2/5

  Singla, 2009 \[[@pone.0161176.ref038]\]                                     India          Cross sectional            45                                          Negative                 Not specified       MDR                6-63m post completion                                                     1961 National TB association USA -diagnostic CXR scoring system\[[@pone.0161176.ref057]\]    Minimal / Moderate / Advanced disease[^¶^](#t004fn004){ref-type="table-fn"}        35.6% Minimal; 22.2% Moderate; 40.0% Advanced                                                                                     1/4

  Lisha, 2012 \[[@pone.0161176.ref048]\]                                      India          Cross sectional            224                                         Not specified            Mixed               Mixed              5 years post completion                                                   1961 National TB association USA -diagnostic CXR scoring system \[[@pone.0161176.ref057]\]   Minimal / Moderate / Advanced disease[^¶^](#t004fn004){ref-type="table-fn"}        34.3% Minimal; 13.4% Moderate; 4.5% Advanced                                                                                      2/4

  Banu Rekha, 2009 \[[@pone.0161176.ref047]\]                                 India          Cross sectional            198                                         Not specified            First episode       Not specified      14--18 years post completion                                              Not specified                                                                                CXR divided into 6 zones. Number of zones involved counted.                        35.9% ≤2 zones; 50% \>2 zones                                                                                                     1/4

  Godoy, 2012 \[[@pone.0161176.ref037]\]                                      Brazil         Cross sectional            18                                          Negative                 Retreatment         MDR                On completion                                                             Wilcox & Ferguson 1989---diagnostic CXR scoring system \[[@pone.0161176.ref058]\]            Grade I---III[^\#^](#t004fn005){ref-type="table-fn"}                               61.1% Grade I; 22.2% Grade II; 16.7% Grade III                                                                                    2/4

  Baez-saldana, 2013 \[[@pone.0161176.ref039]\]                               Mexico         Cross sectional            127                                         Mixed                    Not specified       Not specified      0--252 months post completion                                             Created by authors for grading post-TB CXR changes & validated in study                      CXR split into 4 quadrants. Involvement of each one scored 0--5. Total score 20.   Mean score 6.46/20, standard deviation 4.14                                                                                       2/4

  de la Mora, 2015 \[[@pone.0161176.ref059]\]                                 Mexico         Cross sectional            70[\*\*](#t004fn006){ref-type="table-fn"}   Not specified            Mixed               Mixed              Post completion. With CAO: 2.7+/- 4.3 yrs. Without CAO: 2.3 +/- 2.1 yrs   Not specified                                                                                Number of lung quadrants with fibrocavitatory changes. Total number of cavities    With CAO: 1.8 +/-0.8 affected quadrants, 1.4 +/- 0.8 cavities. Without CAO: 1.3 +/- 0.6 affected quadrants, 0.5 +/-0.7 cavities   1/4

  Kenangalem, 2013 \[[@pone.0161176.ref031]\]                                 Indonesia      RCT---Vit D / L-argenine   77                                          Mixed                    First episode       Mixed              On completion                                                             Ralph 2010---diagnostic CXR scoring system                                                   \% lung affected + 40 if cavitation seen. Total score 140.                         Papuans: Median score 6/140, Range 2--15\                                                                                         2/5
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Non papuans: Median score 12.5/140, Range 4--20.5                                                                                 
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\* Minimal- mild---lung fibrosis \<50% of RUL, no change in architecture/ clouding or lung marking or vasculature. Moderate---lung fibrosis \>50% of RUL, no change in architecture/ clouding or lung marking or vasculature / lung collapse / tortuous airways / bronchiectasis. Advanced---fibrosis of whole RUL, combined with collapse, bronchiectasis and tortuous airways

^†^Minimal---slight to moderate density not containing cavitation with total extent not exceeding lung volume on one side above the chondro-sternal junction. Extensive---slight to moderate density extending more than total volume of one lung or equivalent in both lungs

^‡^Study included patients treated for pulmonary, pleural or mediastinal TB---no disaggregated data available, so all included here

^¶^Minimal---Unilateral or bilateral. Lesions of slight to moderate density with no cavitation. Involvement should not exceed space above 2nd chondrosternal junction and the spine of the 4th or body of 5th vertebra. Moderate---Unilateral or bilateral. Disseminated lesions of slight-moderate density may extend through total volume of 1 lung or equivalent in both lungs. Dense/confluent lesions limited to 1/3 of one lung. Total diameter of cavitation must be \<4cm. Advanced---more extensive than moderate.

^\#^Grade I---minimal change in 1 zone, with no cavities. Grade II---2--3 zones involved, or 1 zone with cavitation. Grade III---severe involvment of \>3zones, with or without cavitation

\*\*Results stratified according to the presence of Chronic Airway Obstruction (CAO) on spirometry, as defined by a ratio of the post-bronchodilator forced expiratory volume in 1 second (FEV~1~) to forced vital capacity (FVC) ratio \<0.7, and the % predicted FEV~1~\< lower limit of normal: patients with CAO (n = 24), without CAO (n = 46). Mean and standard deviation for time since treatment and radiology findings given.

The prevalence of cavitation was higher in studies of re-treatment patients (68.8--83.7%), and those treated for MDR disease (51.5--69.7%), compared to those with fully sensitive, mixed, or unspecified sensitivities (8.3--49.7%). Only 1 study performed repeat imaging; this demonstrated a reduction in the prevalence of cavitation during the 6-month follow-up period from the end of TB treatment, but the findings were limited by a small sample size and 25% loss to follow-up\[[@pone.0161176.ref034]\]

Pleural disease {#sec009}
---------------

The only radiological feature consistently reported in studies of pleural TB sequelae was the presence of residual pleural thickening, but the thoracic area covered by this thickening was not routinely reported. Residual thickening \>10mm was seen in 19.6--46.0% of patients in 4 studies (n = 223) ([Table 5](#pone.0161176.t005){ref-type="table"}). One study reported both CXR and CT findings following pleural TB, with mild pleural thickening \>2mm seen in 50.0% (18/36) on CXR, and 60.0% (21/35) on CT\[[@pone.0161176.ref032]\].

10.1371/journal.pone.0161176.t005

###### Studies of residual pleural thickening (RPT) on completion of treatment for TB pleural effusion.
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  Imaging modality   Author, Year                                 Country        Study design                                             Number of participants   Participant HIV status   Prevalence of pathology (%)        Quality score
  ------------------ -------------------------------------------- -------------- -------------------------------------------------------- ------------------------ ------------------------ ---------------------------------- ---------------
  CXR                Kunter, 2002\[[@pone.0161176.ref060]\]       Turkey         Retrospective cohort                                     47                       Not specified            RPT\>2mm: 63.8% RPT\>10mm: 25.5%   2/5
  CXR                Uskal, 2005\[[@pone.0161176.ref061]\]        Turkey         Retrospective cohort                                     121                      Not specified            RPT\>2mm: 52.1%                    3/5
  CXR                Wong, 2005\[[@pone.0161176.ref062]\]         Hong Kong      Retrospective cohort                                     70                       Not specified            RPT\>10mm: 41.4%                   2/5
  CXR                Barbas, 1991\[[@pone.0161176.ref063]\]       Brazil         Prospective cohort                                       44                       Not specified            RPT\>2mm: 52.3%                    2/5
  CXR                de Pablo, 1997 \[[@pone.0161176.ref064]\]    Spain          Prospective cohort                                       56                       Mixed                    RPT\>2mm: 42.9% RPT\>10mm: 19.6%   3/5
  CXR                Frye, 1997\[[@pone.0161176.ref065]\]         America        Retrospective cohort                                     20                       Positive                 Any RPT: 65.0%                     3/5
  CXR                Galarza, 1995 \[[@pone.0161176.ref033]\]     Spain          RCT---steroid use[\*](#t005fn001){ref-type="table-fn"}   60                       Negative                 Any RPT: 8.3%                      2/5
  CXR                Wyser, 1996 \[[@pone.0161176.ref032]\]       South Africa   RCT---steroid use[\*](#t005fn001){ref-type="table-fn"}   36                       Negative                 RPT\>2mm: 50.0%                    4/5
  CT                 Wyser, 1996 \[[@pone.0161176.ref032]\]       South Africa   RCT---steroid use[\*](#t005fn001){ref-type="table-fn"}   35                       Negative                 RPT\>2mm: 60.0%                    4/5
  CT                 Seiscento, 2007 \[[@pone.0161176.ref066]\]   Brazil         Prospective cohort                                       50                       Not specified            RPT\>10mm: 46.0%                   3/5

\*Date from study arm including steroids excluded

Relationship of imaging changes and other respiratory parameters {#sec010}
----------------------------------------------------------------

Although several studies described spirometry following PTB disease, only 2 studies directly related physiological impairment to imaging findings. The first showed a statistically significant inverse correlation between both FEV~1~ (forced expiratory flow in 1-second) and FVC (forced vital capacity), and the extent of radiographic abnormality on CXR in 127 adults who were a median of 11 months (IQR 6--18 months) post completion of TB treatment\[[@pone.0161176.ref039]\]. The second described imaging findings in patients with (n = 24) and without (n = 46) fixed airway obstruction on spirometry following treatment completion. Those with airway obstruction had had more previous episodes of TB (1.9+/-0.7 vs. 1.4+/-0.6, p = 0.009), but had more fibrocavitatory changes evident on CXR imaging\[[@pone.0161176.ref059]\].

The only study to relate imaging findings to functional capacity included 18 patients completing treatment for MDR-TB, and found a higher level of impairment amongst those with more marked radiographic damage: 64% of those with Grade I damage (7/11) failed to reach an expected 6-minute walking distance, compared to 100% of patients with Grade III damage (3/3). However, the findings of this study were limited by a small sample size and a lack of statistical testing\[[@pone.0161176.ref037]\]. Only one study described the relationship between imaging findings and patient quality of life. This was a cross-sectional study of 198 patients who had been treated for TB a mean of 16.5 years previously, and found no statistically significant difference in the symptoms, activity, impact, or overall St George's Respiratory Questionnaire scores between those with pathology affecting ≤2 vs. \>2 CXR zones\[[@pone.0161176.ref047]\].

Discussion {#sec011}
==========

This review suggests a high prevalence of residual structural lung pathology following PTB treatment, and highlights the contribution that CT imaging may make to our understanding of this pathology. Several gaps in the literature have been identified, including a paucity of prospective data on the evolution of post-TB lung damage over time, limited geographical coverage of studies, little data from HIV-infected adults, and little information on the relationship between structural pathology, physiological abnormalities, and patient centered outcomes.

Despite the increasing focus on long-term patient outcomes within the post-2015 TB agenda, international targets for the management of PTB disease remain microbiologically and mortality driven: standard short course treatment for fully sensitive disease is provided for 6-months with discharge from health services on completion and no routine follow-up thereafter. Thoracic imaging is not routinely performed at the conclusion of treatment, and national TB treatment programmes are required to report data on treatment completion and survival only. Our review describes a high prevalence of residual abnormalities on imaging following medical treatment for PTB, in keeping with existing evidence on the high burden of abnormal airway physiology following PTB\[[@pone.0161176.ref015], [@pone.0161176.ref021]\]. This is particularly high amongst patients treated for MDR disease, which is of concern given the increasing prevalence of drug resistance in many high TB prevalence settings\[[@pone.0161176.ref067]\]. Our review suggests that there may be a substantial burden of undetected lung damage amongst patients completing TB treatment, but that our understanding of the combined structural/physiological nature of this damage, and the consequences of this for patients is limited. There remains insufficient evidence on which to base any changes to imaging and follow-up practices within existing TB programs.

Our review demonstrates differences in the prevalence and patterns of lung damage detected using CXR and CT imaging. CXR studies focused on cavitation, bronchiectasis, and fibrosis, and reported cavitation as the most common finding. In CT studies the prevalence of bronchiectasis was higher than that of cavitation, with possible features of ongoing inflammation (nodules and consolidation), emphysema, and mosaicism which may reflect small airways disease also reported. Whilst access to CT imaging is unlikely to be available in LMICs for routine assessment of patients after PTB treatment, limited use within research studies may have a role in accurately phenotyping disease, and identifying pathologies that could otherwise be missed. Studies performing paired CXR and CT imaging after pulmonary TB will then be required to determine the sensitivity of CXR imaging used within National Treatment Programs in LMICS for this CT defined structural damage.

Efforts to better define post-TB lung pathology will need to include an understanding of its evolution over time if we are to improve long-term patient outcomes. We identified a paucity of prospective data on the trajectory of imaging defined post-TB lung disease. This limitation is also seen in our understanding of the evolution of lung function following PTB, which is based on cross-sectional studies\[[@pone.0161176.ref068]\]. Uncertainty therefore remains about the rate and drivers of recovery/deterioration in those with post-TB lung damage. Factors influencing the progression of lung damage may include modifiable exposures such as smoking, biomass fuel\[[@pone.0161176.ref069], [@pone.0161176.ref070]\], and ongoing respiratory tract infections\[[@pone.0161176.ref071]\]. Further research in this area may inform strategies to prevent decline in this group.

Few studies attempted to examine the relationship between lung damage and patient functional capacity, symptom burden, and quality of life. The available data suggest that exercise capacity may decrease with increasing extents of structural pathology, but sample sizes in the one study to assess this were low\[[@pone.0161176.ref037]\]. The only study relating structural pathology to quality of life was vulnerable to selection bias, and the nature of this relationship therefore remains unclear\[[@pone.0161176.ref047]\]. A cohort study of patients with extensively destroyed lung after TB disease has confirmed a high incidence of infective exacerbations and mortality in this group\[[@pone.0161176.ref072]\], but further prospective data are required on outcomes amongst those with residual respiratory damage of a broader range of patterns and severity, from the time of treatment.

We identified a paucity of data from sSA and from HIV-positive patients. Given the convergence of a high TB prevalence and multiple risk factors for disease progression in sSA, data from this region is critical to our understanding of the public health impact of residual lung damage following TB treatment. HIV-positive individuals have a higher risk of developing TB disease, so should also be a focus of research. Although this group have atypical PTB presentations, with less structural damage seen at diagnosis\[[@pone.0161176.ref073]\], they may experience a differential pattern of progression of lung disease during or after treatment due to the effects of opportunistic infections, immune reconstitution syndrome and HIV-related immune activation on the lung\[[@pone.0161176.ref067], [@pone.0161176.ref074]--[@pone.0161176.ref076]\]. HIV-positive patients may also be particularly vulnerable to decreased quality of life and impaired functional capacity related to residual damage, and further analysis of respiratory outcomes in this group is urgently required\[[@pone.0161176.ref077]\].

The quality of studies identified in this review varied substantially. None included imaging prior to TB diagnosis, thus the presence of structural damage present prior to TB disease was not truly excluded. The majority of studies failed to specify how the radiological abnormalities reported on imaging were defined, and did not use gold-standard methods of reporting, making them vulnerable to misclassification of outcomes. Selection bias was a common issue; many studies were unclear about the reference population from which participants were drawn. The cross-sectional studies imaging patients sometime after treatment completion consistently struggled to locate eligible patients, and were limited by survival bias.

The strengths of our review include the use of several databases with no limitation on study dates, and the use of reference and citation review to identify additional papers. The study is limited by the inclusion of English language articles only. The heterogeneity of patient populations, treatment regimens, and the timing and modality of imaging meant that we were unable to perform a meta-analysis.

Conclusion {#sec012}
==========

This systematic review identified a high burden of structural pathology after PTB treatment. A better understanding of the nature of this pathology, evolution of disease over time, factors driving deterioration, and the impact of respiratory pathology on patients' lives and livelihoods is needed to guide clinical management and health-service planning. Data on the sensitivity of CXR and spirometric indices for structural changes seen on CT imaging are required, together with studies examining post-TB lung damage in HIV-infected individuals and those from sSA. Further investigation of these areas is required if we are to meet the post-2015 TB aim of reducing the long-term detrimental impact of TB disease on patients' lives and livelihoods.
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